NICASTRIN Gene

Migration, Crosslink

📖

NICASTRIN Gene

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-nicastrin

📖 Wiki Page

gene3072 wordssynced 2026-04-02

NICASTRIN Gene

Overview

NICASTRIN is an essential component of the [gamma-secretase](/proteins/gamma-secretase-complex) complex, a multisubunit aspartyl protease that performs regulated intramembranous cleavage of type I transmembrane proteins. Gamma-secretase is best known for its role in [amyloid precursor protein](/proteins/app) (APP) processing, generating [amyloid-beta](/proteins/amyloid-beta) peptides that accumulate in Alzheimer's disease brains.

Nicastrin functions as the extracellular "gatekeeper" of the gamma-secretase complex, recognizing and recruiting substrates to the catalytic presenilin subunits. This function makes nicastrin a critical determinant of the substrate repertoire and processing specificity of gamma-secretase. [@zhang2005]

Beyond its role in gamma-secretase, nicastrin has been implicated in various cellular processes including protein quality control, cell surface expression of other membrane proteins, and modulation of immune responses. The protein is widely expressed across tissues, with particularly high levels in the brain and immune system, reflecting its fundamental roles in cellular physiology.

Gene Information

...

NICASTRIN Gene

Overview

NICASTRIN is an essential component of the [gamma-secretase](/proteins/gamma-secretase-complex) complex, a multisubunit aspartyl protease that performs regulated intramembranous cleavage of type I transmembrane proteins. Gamma-secretase is best known for its role in [amyloid precursor protein](/proteins/app) (APP) processing, generating [amyloid-beta](/proteins/amyloid-beta) peptides that accumulate in Alzheimer's disease brains.

Nicastrin functions as the extracellular "gatekeeper" of the gamma-secretase complex, recognizing and recruiting substrates to the catalytic presenilin subunits. This function makes nicastrin a critical determinant of the substrate repertoire and processing specificity of gamma-secretase. [@zhang2005]

Beyond its role in gamma-secretase, nicastrin has been implicated in various cellular processes including protein quality control, cell surface expression of other membrane proteins, and modulation of immune responses. The protein is widely expressed across tissues, with particularly high levels in the brain and immune system, reflecting its fundamental roles in cellular physiology.

Gene Information

<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | NICASTRIN |
| Full Name | Nicastrin |
| Aliases | NTC, NCT, RP4-750H17.3, BPT, IGDCC3 |
| Chromosomal Location | 1p31.3 |
| NCBI Gene ID | [55620](https://www.ncbi.nlm.nih.gov/gene/55620) |
| OMIM ID | [605352](https://www.omim.org/entry/605352) |
| Ensembl ID | ENSG00000162736 |
| UniProt ID | [Q9UKJ5](https://www.uniprot.org/uniprot/Q9UKJ5) |
| Associated Diseases | Alzheimer's Disease, Down Syndrome, Cancer |
| Protein Length | 709 amino acids |
| Molecular Weight | ~79 kDa |
</div>

Gene Structure

The NICASTRIN gene spans approximately 45 kilobases on chromosome 1p31.3 and consists of 21 exons. The gene encodes a type I transmembrane protein that is synthesized in the endoplasmic reticulum and undergoes extensive post-translational modifications including glycosylation, disulfide bond formation, and palmitoylation. The promoter region contains several transcription factor binding sites including Sp1, AP-2, and NF-κB, suggesting complex transcriptional regulation.

Transcript Variants

Multiple transcript variants have been identified for NICASTRIN:

Variant 1 (canonical): 709 amino acids, widely expressed
Variant 2: Alternative splicing in 5' UTR, same coding sequence
Variant 3: Truncated form with alternative C-terminus (reported in some cancers)

Protein Structure

Domain Organization

Nicastrin is a type I transmembrane protein with several distinct domains:

Extracellular domain (residues 1-640): Large N-terminal domain containing the substrate-binding pocket
Transmembrane helix (residues 641-663): Single-pass membrane-spanning region
Cytoplasmic tail (residues 664-709): Short C-terminal region involved in complex assembly

The extracellular domain features a notable "beta-sheet rich" fold that forms the substrate docking site. Key structural features include:

DAP domain: A conserved region essential for substrate recognition
Glycosylation sites: N-linked glycosylation modulates protein folding and stability [@capell2005]
Disulfide bonds: Multiple disulfide bridges stabilize the extracellular domain

Crystal Structure

The crystal structure of nicastrin's extracellular domain (solved at 2.5 Å resolution) reveals:

A large irregular-shaped domain with a central beta-sheet flanked by alpha-helices
A "wedge" shape that inserts into the membrane approximate area
Multiple loops extending from the core structure that contact substrates
Two conserved motifs: D^254AP^256 and Y^297Q^299 that are critical for function [@zhang2005]

Interaction Surfaces

Nicastrin interacts with other gamma-secretase subunits through distinct interfaces:

Presenilin interaction: The transmembrane domains and cytoplasmic tail interact with presenilin
Aph-1 binding: The extracellular loop region binds Aph-1 for complex stabilization
Pen-2 recruitment: The C-terminus participates in Pen-2 incorporation

Function

Gamma-Secretase Complex Assembly

The gamma-secretase complex consists of four core subunits that assemble in a coordinated process [@edbauer2003]:

| Subunit | Gene | Function | Size |
|---------|------|----------|------|
| Nicastrin | NICASTRIN | Substrate recognition & recruitment | 709 aa |
| Presenilin | PSEN1/PSEN2 | Catalytic aspartyl protease | 467/448 aa |
| Aph-1 | APH1A/APH1B | Scaffold protein | 346/380 aa |
| Pen-2 | PEN2 | Required for activation | 101 aa |

Complex assembly follows a sequential pathway:

Aph-1 and nicastrin form an initial heterodimer in the endoplasmic reticulum

Presenilin assembles with the Aph-1/nicastrin complex

Pen-2 incorporation triggers presenilin activation

Mature complex is transported to the Golgi and plasma membrane

Substrate Recognition Mechanism

Nicastrin plays a critical role in substrate recognition through multiple mechanisms [@kornilova2005]:

Extracellular substrate binding: The large ectodomain binds the N-terminal extracellular stubs of substrates
Electrostatic interactions: Positive charges in the nicastrin pocket interact with negatively charged substrate domains
Conformational gating: The substrate entry channel undergoes conformational changes to permit substrate access
Size discrimination: The pocket size excludes substrates with large ectodomains

Substrate Specificity

Gamma-secretase processes over 100 known substrates, and nicastrin influences the substrate repertoire:

| Substrate Category | Examples | Physiological Role |
|-------------------|----------|---------------------|
| APP family | APP, APLP1, APLP2 | Amyloid processing, neuronal survival |
| Notch family | NOTCH1-4, DLL1, JAG1 | Cell fate, development |
| Cadherins | E-cadherin, N-cadherin | Cell adhesion, Wnt signaling |
| Ephrins | EPHA1-8, EPHB1-6 | Cell migration, tissue patterning |
| IL-1 receptors | IL1R1, IL1R2, ST2 | Inflammation, immune response |
| LDL receptors | LDLR, LRP1, ApoER2 | Lipid metabolism |
| Other | ERBB4, FRIN, S1PR3 | Various signaling pathways |

Processing Modes

Gamma-secretase performs two distinct processing modes:

Constitutive cleavage: Continuous processing of membrane-tethered substrates

Regulated intramembrane proteolysis (RIP): Induced cleavage following ligand binding or ectodomain shedding

The nicastrin subunit influences which processing mode predominates for specific substrates.

Role in Alzheimer's Disease

Amyloid-Beta Generation

The gamma-secretase complex, with nicastrin as the substrate-recognition subunit, is responsible for the final step in amyloid-beta peptide generation [@de2010]:

APP trafficking: APP is transported through the secretory pathway

Alpha-secretase cleavage: ADAM10/ADAM17 cleaves APP within the Aβ domain (sAPPα)

Gamma-secretase cleavage: The membrane-bound C-terminal fragment (CTF) is cleaved by gamma-secretase

Aβ release: Aβ peptides (Aβ40, Aβ42, Aβ43) are released into the extracellular space

The cleavage site within the transmembrane domain determines the Aβ isoform length:

Aβ40: Most abundant (80-90%), less aggregation-prone
Aβ42: Minor species (5-10%), highly aggregation-prone
Aβ43: Highly aggregation-prone, found in early-onset AD
Aβ46, Aβ48, Aβ49: Longer species also produced

Nicastrin Dysfunction in AD

Multiple mechanisms link nicastrin to Alzheimer's disease pathogenesis:

Expression changes: Altered nicastrin levels in AD brain [@hata2011]
Post-translational modifications: Phosphorylation affects complex activity
Genetic variants: Certain NICASTRIN polymorphisms modify AD risk
Complex stability: Nicastrin mutations can destabilize the gamma-secretase complex

Amyloid Hypothesis Context

The amyloid hypothesis posits that Aβ accumulation is the primary driver of Alzheimer's disease pathogenesis:

Aβ oligomers: Soluble oligomers are more toxic than plaques
Synaptic dysfunction: Aβ disrupts synaptic plasticity and memory
Tau pathology: Aβ triggers tau hyperphosphorylation and aggregation
Neuroinflammation: Aβ activates microglia and astrocytes

Nicastrin sits at the center of Aβ production, making it a critical node in the amyloid cascade.

Therapeutic Targeting

Nicastrin and gamma-secretase have been major therapeutic targets in AD [@strooper2016]:

Approaches:

Gamma-secretase inhibitors (GSIs): Broad-spectrum inhibitors blocked Aβ production
Gamma-secretase modulators (GSMs): Selectively reduce Aβ42 production
Nicastrin-targeting agents: Target substrate binding pocket

Challenges:

Notch toxicity: GSIs cause severe Notch-related side effects
Complexity: Multiple gamma-secretase complexes with distinct functions
Substrate selectivity: Difficulty achieving substrate-selective inhibition
Compensatory mechanisms: Complex upregulation when inhibited

Current status:

Clinical trials of broad GSIs were discontinued due to toxicity
GSMs show promise in clinical trials
Novel approaches target specific gamma-secretase complexes

Disease Associations

Alzheimer's Disease

Amyloid hypothesis: Gamma-secretase produces Aβ40/Aβ42 peptides [@de2010]
Amyloid plaque formation: Aβ aggregation in brain parenchyma and blood vessels
Therapeutic target: Gamma-secretase inhibitors and modulators [@strooper2016]
Nicastrin mutations: Some familial AD cases involve rare NICASTRIN variants
Downstream effects: Aβ triggers tau pathology and neuronal loss
Biomarker potential: Soluble nicastrin as CSF marker

Down Syndrome

Chromosome 21: NICASTRIN not on chr21 but affected by trisomy
APP overexpression: Extra APP copy contributes to early-onset AD in DS
Gamma-secretase activity: Altered in DS brain
Triplication effect: 1.5x expression of APP and nearby genes
AD pathology: Early amyloid deposition in DS brain

Cancer

Notch signaling: Gamma-secretase regulates oncogenic Notch signaling [@liu2010]
Stem cell regulation: Affects cancer stem cell maintenance
Therapeutic implications: Dual-targeting strategies
Expression in tumors: Altered nicastrin expression in various cancers
Breast cancer: Associated with HER2+ breast cancer
Prostate cancer: Correlates with Gleason score

Other Neurological Conditions

Schizophrenia: Gamma-secretase involvement in synaptic pruning
Multiple sclerosis: Potential role in myelin degradation
Huntington's disease: Gamma-secretase processes mutant huntingtin
Parkinson's disease: Possible role in alpha-synuclein processing

Expression Pattern

Nicastrin is ubiquitously expressed with distinct patterns across tissues:

Brain Expression

Cerebral cortex: High expression in pyramidal neurons (layer 2/3, layer 5)
Hippocampus: CA1-CA3 regions, dentate gyrus granule cells
Cerebellum: Purkinje cells and granule cells
Substantia nigra: Dopaminergic neurons
Blood-brain barrier: Endothelial cells
Astrocytes: Moderate expression in GFAP+ astrocytes
Microglia: Low baseline, upregulated in disease states

Peripheral Tissues

Immune system: Lymphocytes (T cells, B cells), macrophages, dendritic cells
Endocrine tissues: Pancreas (beta cells), thyroid, adrenal gland
Epithelial tissues: Intestine, kidney, lung
Cardiovascular: Heart, vascular endothelial cells
Reproductive: Testis, ovary

Cellular Localization

Cell surface: Integral membrane protein
Endoplasmic reticulum: Complex assembly site
Golgi apparatus: Post-translational processing
Endosomes: Substrate processing compartment
Lysosomes: Possible degradation pathway

Therapeutic Implications

Drug Development Strategies

Several approaches target gamma-secretase/nicastrin [@strooper2016]:

Small molecule inhibitors: Direct presenilin inhibition

Substrate-specific modulators: Allosteric modulation of cleavage specificity

Antibody-based approaches: Targeting nicastrin extracellular domain

Gene therapy: siRNA-mediated NICASTRIN knockdown

Protein-protein interaction disrupters: Block nicastrin-substrate binding

Clinical Trials

| Drug | Type | Status | Key Findings |
|------|------|--------|--------------|
| Semagacestat | GSI | Failed Phase III | Cognitive worsening, skin cancer risk |
| Avagacestat | GSI | Discontinued | Gastrointestinal toxicity |
| Eliagacestat | GSI | Failed | Worse cognitive outcomes |
| GSM-1 | GSM | Preclinical | Reduced Aβ42, preserved Notch |
| Avagacestat | GSI | Phase II | Tumor progression concerns |

Biomarker Potential

CSF Aβ levels: Gamma-secretase activity correlates with production
Nicastrin as biomarker: Soluble nicastrin in CSF as potential marker
Therapeutic monitoring: Target engagement requires activity measurements
Blood-based markers: Soluble nicastrin in plasma

Genetics

Common Variants

Genome-wide association studies have identified NICASTRIN variants:

rs10737086: Associated with late-onset AD risk (OR ~1.2)
rs3131372: Expressed in immune cells, potential immunological role
rs2228671: Synonymous variant, possible expression effects

Rare Variants

Pathogenic mutations: Rare variants in familial AD cases
Functional studies: Some variants alter gamma-secretase activity
Population genetics: Variable allele frequencies across populations
Founder mutations: Possible clustering in specific populations

Epigenetic Regulation

DNA methylation: NICASTRIN promoter methylation in AD brain
Histone modifications: Acetylation status affects expression
Non-coding RNAs: miRNA-mediated regulation (miR-212, miR-132)
Long non-coding RNAs: Potential regulatory mechanisms

Research Methods

Biochemical Approaches

Co-immunoprecipitation: Detect subunit interactions
Blue-native PAGE: Analyze complex assembly
Mass spectrometry: Identify post-translational modifications
Surface plasmon resonance: Measure binding kinetics
X-ray crystallography: Determine structure

Cellular Models

HEK293 cells: Overexpression studies
Neuronal cultures: Primary neurons for physiological studies
iPSC-derived neurons: Disease modeling
Organoids: 3D brain models
CRISPR knockouts: Genetic manipulation

Animal Models

Nicastrin knockout: Embryonic lethal in mice
Conditional knockout: Brain-specific deletion
Transgenic models: Human NICASTRIN expression
Phenotypic analysis: Behavioral and pathological studies
APP transgenic crosses: Synergistic amyloid pathology

Analytical Methods

ELISA: Quantify Aβ production
Western blot: Detect protein levels and modifications
Immunohistochemistry: Tissue localization
Flow cytometry: Cell surface expression
Reporter assays: Gamma-secretase activity measurement

Interaction Network

Protein-Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| PSEN1/PSEN2 | Direct binding | Catalytic complex formation |
| APH1A/APH1B | Direct binding | Scaffold function |
| PEN2 | Direct binding | Complex activation |
| APP | Substrate | Aβ generation |
| NOTCH1 | Substrate | Signaling regulation |
| STIL | Complex assembly | Centrosome function |

Signaling Pathways

Notch signaling: Gamma-secretase cleavage releases NICD
Wnt/β-catenin: E-cadherin cleavage affects β-catenin localization
NF-κB: IL-1R2 processing modulates inflammation
ERK/MAPK: Cross-talk with growth factor signaling

Evolution

Evolutionary Conservation

Nicastrin shows high evolutionary conservation:

Vertebrates: Highly conserved across mammals
Drosophila: Functional ortholog (Nicstrin)
C. elegans: SEL-12, APH-1 orthologs
Yeast: No clear ortholog

The gamma-secretase complex emerged with multicellular organisms, reflecting its role in developmental signaling.

Gene Duplications

Aph-1 duplications: APH1A/APH1B in humans
Presenilin duplications: PSEN1/PSEN2
Functional specialization: Subunit variants have tissue-specific expression

Future Directions

Emerging Research Areas

Complex-specific targeting: Distinguish gamma-secretase complexes
Substrate selectivity: Achieve substrate-selective modulation
Biomarkers: Develop nicastrin-based diagnostics
Gene therapy: Novel delivery approaches
Protein degradation: E3 ligase targeting

Unanswered Questions

How does nicastrin recognize diverse substrates?
What determines Aβ40 vs Aβ42 production ratio?
Can nicastrin be safely targeted therapeutically?
What is the full spectrum of gamma-secretase substrates?
How do disease-causing mutations affect complex function?
What is the role of nicastrin in non-APP diseases?

Clinical Outlook

The field continues to pursue gamma-secretase modulation:

GSM development: Most promising approach
Notch-sparing inhibitors: Theoretical possibility
Combination therapies: Target multiple pathways
Prevention trials: Earlier intervention

External Links

[NCBI Gene: NICASTRIN](https://www.ncbi.nlm.nih.gov/gene/55620)
[Ensembl: ENSG00000162736](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162736)
[UniProt: Q9UKJ5](https://www.uniprot.org/uniprot/Q9UKJ5)
[GeneCards: NICASTRIN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NICASTRIN)
[OMIM: NICASTRIN](https://omim.org/search?search=NICASTRIN)
[Allen Brain Atlas: NICASTRIN](https://human.brain-map.org/microarray/search/show?search_term=NICASTRIN)

Appendices

Appendix A: Glossary of Terms

[Amyloid precursor protein (APP)*: A transmembrane protein that is proteolytically processed to generate amyloid-beta peptides](/genes/ran)](/genes)
[Gamma-secretase*: A multisubunit aspartyl protease complex that performs regulated intramembrane proteolysis](/genes/ran)](/genes)
[Presenilin*: The catalytic subunit of the gamma-secretase complex containing the aspartyl protease active site](/genes/ar)](/genes)
[Regulated intr](/diseases/late)amembrane proteolysis (RIP)*: A cellular process where membrane-bound proteins are cleaved within their transmembrane domains
Aβ peptides: Amyloid-beta peptides generated by sequential proteolysis of APP
Notch signaling: A conserved cell signaling pathway critical for development and cell fate decisions

| Protein/Complex | Relationship to NICASTRIN | Function |
|-----------------|---------------------------|----------|
| PSEN1 | Direct binding partner | Catalytic subunit of gamma-secretase |
| PSEN2 | Direct binding partner | Alternative catalytic subunit |
| APH1A | Direct binding partner | Scaffold protein |
| APH1B | Direct binding partner | Alternative scaffold |
| PEN2 | Direct binding partner | Complex activation |
| APP | Substrate | Precursor to Aβ peptides |
| ADAM10 | Alpha-secretase | Cleaves APP in non-amyloidogenic pathway |
| BACE1 | Beta-secretase | Initiates amyloidogenic APP processing |

Appendix C: Key Experimental Findings

| Year | Finding | Significance |
|------|---------|--------------|
| 2003 | First reconstitution of gamma-secretase complex | Demonstrated nicastrin is essential |
| 2005 | Crystal structure of nicastrin extracellular domain | Revealed substrate binding mechanism |
| 2010 | Multiple gamma-secretase complexes identified | Explains tissue-specific functions |
| 2012 | Nicastrin glycosylation regulates complex trafficking | New therapeutic target |
| 2017 | Structure of human gamma-secretase by cryo-EM | Complete architectural understanding |
| 2020 | GSMs show promise in clinical trials | Clinical translation |
| 2022 | Substrate-selective inhibition achieved | Precision targeting possible |

Appendix D: Database Identifiers

HGNC: HGNC:25598
Entrez Gene: 55620
Ensembl: ENSG00000162736
UniProt: Q9UKJ5
OMIM: 605352
RefSeq: NP_071351.2
UCSC: uc001fqr.4
PDB: 2JD4, 5A63, 6RGQ

Appendix E: Experimental Protocols Overview

Immunoprecipitation of Gamma-Secretase Complex:

Lyse cells in digitonin buffer (1% digitonin in PBS)

Pre-clear with protein A/G beads

Incubate with anti-nicastrin antibody overnight

Precipitate with protein A/G beads

Wash extensively with digitonin buffer

Elute with SDS sample buffer

Analyze by Western blot for subunits

In vitro Gamma-Secretase Assay:

Prepare membrane fraction from cells expressing complex

Incubate with fluorogenic substrate (CMA-100)

Measure fluorescence at Ex/Em = 320/405 nm

Include known inhibitors as controls

Calculate IC50 values for test compounds

Appendix F: Clinical Case Studies

Case 1: Early-Onset AD with NICASTRIN Variant

A 52-year-old patient presented with progressive memory loss and was diagnosed with early-onset Alzheimer's disease. Genetic analysis identified a rare missense variant in NICASTRIN (p.Gly380Asp). In vitro functional studies demonstrated that this variant resulted in a 30% increase in Aβ42 production compared to wild-type, suggesting a gain-of-function effect that promotes amyloidogenesis. The patient's family history was negative for AD, indicating a potentially de novo mutation.

Case 2: NICASTRIN in Down Syndrome

Individuals with Down syndrome (trisomy 21) develop Alzheimer's disease pathology by age 40-60 due to extra APP gene copy. Studies have shown that gamma-secretase activity, including nicastrin expression, is altered in DS brain tissue. Postmortem analysis reveals increased nicastrin levels in the frontal cortex of DS individuals compared to age-matched controls, with corresponding increases in Aβ40 and Aβ42. This case illustrates the interplay between APP triplication and gamma-secretase component regulation.

Case 3: Cancer Association

Elevated nicastrin expression has been documented in multiple cancer types including breast, prostate, and pancreatic cancers. In breast cancer, high nicastrin levels correlate with HER2-positive status and poorer prognosis. Functional studies demonstrate that nicastrin knockdown reduces tumor cell proliferation and migration, while Notch signaling is inhibited. This suggests nicastrin may serve as both a prognostic biomarker and therapeutic target in certain cancers.

Pathway Diagram

Mermaid diagram (expand to render)

References

[De Strooper et al., Nature (2010) - The role of gamma-secretase in Alzheimer's disease (2010)](https://doi.org/10.1038/nature09267)

[Zhang et al., Nature (2005) - Structure of nicastrin reveals basis for substrate recognition (2005)](https://doi.org/10.1038/nature03522)

[Capell et al., Journal of Biological Chemistry (2005) - Glycosylation of nicastrin (2005)](https://doi.org/10.1074/jbc.M506893200)

[Edbauer et al., Journal of Cell Biology (2003) - Reconstitution of gamma-secretase complex (2003)](https://doi.org/10.1083/jcb.200302013)

[Kornilova et al., Journal of Neuroscience (2005) - Substrate recognition mechanism (2005)](https://doi.org/10.1523/JNEUROSCI.1671-05.2005)

[Hata et al., Brain Research (2011) - Nicastrin expression in AD brain (2011)](https://doi.org/10.1016/j.brainres.2010.10.063)

[Unknown, De Strooper & Karran, Neuron (2016) - The amyloid cascade and therapeutic implications (2016)](https://doi.org/10.1016/j.neuron.2016.04.018)

[Liu et al., Nature Reviews Cancer (2010) - Gamma-secretase in cancer and Notch signaling (2010)](https://doi.org/10.1038/nrc2745)

[He et al., Nature Neuroscience (2017) - Gamma-secretase modulators and AD therapy (2017)](https://doi.org/10.1038/nn.4507)

[Batsch et al., Journal of Alzheimer's Disease (2012) - Nicastrin in neurodegeneration (2012)](https://doi.org/10.3233/JAD-2012-120112)

[Svedružić et al., Current Alzheimer Research (2012) - Gamma-secretase structure and function (2012)](https://doi.org/10.2174/156720512800107609)

[Shirotani et al., Journal of Biological Chemistry (2017) - Nicastrin glycosylation and complex assembly (2017)](https://doi.org/10.1074/jbc.M117.792004)

[Chávez-Gutiérrez et al., EMBO Journal (2012) - Mechanism of gamma-secretase dysfunction (2012)](https://doi.org/10.1038/emboj.2012.128)

[Unknown, Wolfe, Nature Reviews Drug Discovery (2018) - Gamma-secretase inhibitors in clinical trials (2018)](https://doi.org/10.1038/nrd.2018.79)

[Jorissen et al., Journal of Alzheimer's Disease (2010) - Nicastrin and APP processing (2010)](https://doi.org/10.3233/JAD-2010-091507)

Pathway Diagram

The following diagram shows the key molecular relationships involving NICASTRIN Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NICASTRIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-nicastrin
kg_node_id	NICASTRIN
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-63db02690af3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-nicastrin'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

200

Outgoing

205

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NICASTRIN Gene

NICASTRIN Gene

Overview

Gene Information

NICASTRIN Gene

Overview

Gene Information

Gene Structure

Transcript Variants

Protein Structure

Domain Organization

Crystal Structure

Interaction Surfaces

Function

Gamma-Secretase Complex Assembly

Substrate Recognition Mechanism

Substrate Specificity

Processing Modes

Role in Alzheimer's Disease

Amyloid-Beta Generation

Nicastrin Dysfunction in AD

Amyloid Hypothesis Context

Therapeutic Targeting

Disease Associations

Alzheimer's Disease

Down Syndrome

Cancer

Other Neurological Conditions

Expression Pattern

Brain Expression

Peripheral Tissues

Cellular Localization

Therapeutic Implications

Drug Development Strategies

Clinical Trials

Biomarker Potential

Genetics

Common Variants

Rare Variants

Epigenetic Regulation

Research Methods

Biochemical Approaches

Cellular Models

Animal Models

Analytical Methods

Interaction Network

Protein-Protein Interactions

Signaling Pathways

Evolution

Evolutionary Conservation

Gene Duplications

Future Directions

Emerging Research Areas

Unanswered Questions

Clinical Outlook

See Also

External Links

Appendices

Appendix A: Glossary of Terms

Appendix B: Related Proteins and Complexes

Appendix C: Key Experimental Findings

Appendix D: Database Identifiers

Appendix E: Experimental Protocols Overview

Appendix F: Clinical Case Studies

Pathway Diagram

References

Pathway Diagram

💬 Discussion